生血宝合剂联合生血宁片治疗妊娠期缺铁性贫血的疗效观察

Clinical observation of Shengxuebao Mistura combined with Shengxuening Tablets in treatment of iron deficiency anemia in pregnancy

目的探究生血宝合剂联合生血宁片治疗妊娠期缺铁性贫血的临床疗效。方法选取2013年1月—2016年1月北京市顺义区医院就诊的妊娠期缺铁性贫血的妇女126例,根据随机数表法将全部患者随机分为对照组和治疗组,每组各63例,对照组患者口服生血宁片,0.5 g/次,2~3次/d;治疗组患者在对照组的基础上口服生血宝合剂,15 m L/次,3次/d。两组患者均治疗3个月。治疗后,观察两组的临床疗效,比较两组的血液学指标和不良反应情况。结果治疗后,对照组和治疗组的总有效率分别为79.36%、92.06%,两组比较差异有统计学意义(P<0.05);两组红细胞计数(RBC)、血红蛋白(Hb)、血清铁(SI)和铁蛋白饱和度(TSAT)水平均显著升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组这些观察指标的升高程度明显优于对照组,两组比较差异具有统计学意义(P<0.05);治疗组的不良反应总发生率为7.93%,显著低于对照组(17.46%),两组比较差异具有统计学意义(P<0.05)。结论生血宝合剂联合生血宁片治疗妊娠期缺铁性贫血患者能够取得更为优异的疗效,对患者各项血液学相关指标水平也有着调节作用,在一定程度上能够降低患者治疗过程中出现的不良反应发生率,具有一定的临床推广应用价值。

Objective To explore Shengxuebao Mistura combined with Shengxuening Tablets in treatment of iron deficiency anemia in pregnancy. Methods A total of 126 pregnant women with iron deficiency anemia were selected in Beijing Shunyi District Hospital from January 2013 to January 2016. According to the random number table method, all patients were randomly divided into control and treatment groups, and each group had 63 cases. Patients in the control group were po administered with Shengxuening Tablets, 0.5 g/time, 2 — 3 times daily. Patients in the treatment group were po administered with Shengxuebao Mistura, 5 mL/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and hematology indexes and adverse reactions in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.36% and 92.06%, respectively, and there was difference between two groups（P〈0.05）. After treatment, the levels of RBC, Hb, SI, and TSAT in two groups were significantly increased, and the difference was statistically significant in the same group（P〈0.05）. The observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups（P〈0.05）. The incidence rate of adverse reactions in the treatment group was 7.93%, which was significantly lower than 17.46% in the control group, with significant difference between two groups（P〈0.05）. Conclusion Shengxuebao Mistura combined with Shengxuening Tablets has more excellent curative effect in treatment of iron deficiency anemia in pregnancy, also has a regulatory role in the levels of various hematology indexes, and can reduce the adverse effects rate, which has a certain clinical application value.